{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:16:17Z","timestamp":1783462577360,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>\n                        <jats:bold>Abstract<\/jats:bold>\n                     <\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lipegfilgrastim has been shown to be non-inferior to pegfilgrastim for reduction of the duration of severe neutropenia (DSN) in breast cancer patients. This open-label, non-inferiority study assessed the efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (NHL) at high risk for chemotherapy-induced neutropenia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patient and methods<\/jats:title>\n                <jats:p>One hundred and one patients (median age, 75 years) were randomized to lipegfilgrastim or pegfilgrastim (6 mg\/cycle) during six cycles of R-CHOP21.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Lipegfilgrastim was non-inferior to pegfilgrastim for the primary efficacy endpoint, reduction of DSN in cycle 1. In the per-protocol population, mean (standard deviation) DSN was 0.8 (0.92) and 0.9 (1.11) days in the two groups, respectively; the adjusted mean difference between groups was \u2212 0.3 days (95% confidence interval, \u2212 0.70 to 0.19). Non-inferiority was also demonstrated in the intent-to-treat population. The incidence of severe neutropenia in cycle 1 was 51% (21\/41) in the lipegfilgrastim group and 52% (23\/44) in the pegfilgrastim group. Very severe neutropenia (ANC &lt; 0.1 \u00d7 10<jats:sup>9<\/jats:sup>\/L) in cycle 1 was reported by 5 (12%) patients in the lipegfilgrastim group and 8 (18%) patients in the pegfilgrastim group. However, over all cycles, febrile neutropenia (strict definition) was reported by only 1 (2%) patient in each treatment group (during cycle 1 in the lipegfilgrastim group and cycle 6 in the pegfilgrastim group). The mean time to absolute neutrophil count recovery (defined as \u2265 2.0 \u00d7 10<jats:sup>9<\/jats:sup>\/L) was 8.3 and 9.4 days in the two groups, respectively. Serious adverse events occurred in 46% of patients in each group; none were considered treatment-related. Eight patients died during the study (2 in the lipegfilgrastim group, 5 in the pegfilgrastim group, and 1 who died before starting study treatment). No deaths occurred during the treatment period, and all were considered to be related to the underlying disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study shows lipegfilgrastim to be non-inferior to pegfilgrastim for the reduction of DSN in elderly patients with aggressive B cell NHL receiving myelosuppressive chemotherapy, with a comparable safety profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifier NCT02044276; EudraCT number 2013-001284-23<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-020-05711-7","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T21:03:56Z","timestamp":1600376636000},"page":"2519-2527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-0265","authenticated-orcid":false,"given":"Hartmut","family":"Link","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Illerhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Salar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Depenbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mahlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lammerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"issue":"4","key":"5711_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242","journal-title":"N Engl J Med"},{"issue":"9880","key":"5711_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381(9880):1817\u20131826","journal-title":"Lancet"},{"issue":"6","key":"5711_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","volume":"14","author":"R Delarue","year":"2013","unstructured":"Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesqui\u00e8res H, Hacini M, Fruchart C, Ysebaert L, Ferm\u00e9 C, Casasnovas O, van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A (2013) Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14(6):525\u2013533","journal-title":"Lancet Oncol"},{"key":"5711_CR4","unstructured":"National Cancer Institutes. Common Terminology Criteria for Adverse Advents v4.03 (Excel). June 14, 2010. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed 29 June 2020"},{"issue":"10","key":"5711_CR5","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24(10):2475\u20132484","journal-title":"Ann Oncol"},{"issue":"6","key":"5711_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","volume":"8","author":"LW Kwak","year":"1990","unstructured":"Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8(6):963\u2013977","journal-title":"J Clin Oncol"},{"issue":"4","key":"5711_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","volume":"87","author":"A Bosly","year":"2008","unstructured":"Bosly A, Bron D, Van Hoof A et al (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87(4):277\u2013283","journal-title":"Ann Hematol"},{"issue":"5","key":"5711_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-008-0447-2","volume":"87","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Bosly A (2008) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 87(5):429\u2013430","journal-title":"Ann Hematol"},{"issue":"1","key":"5711_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Lago LD, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"issue":"28","key":"5711_CR10","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"key":"5711_CR11","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, ESMO Guidelines Committee (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27:v111\u2013v118","journal-title":"Ann Oncol"},{"key":"5711_CR12","unstructured":"European Medicines Agency. Lonquex 6 mg solution for injection in pre-filled syringe. Summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lonquex-epar-product-information_en.pdf. Accessed 29 June 2020."},{"issue":"21","key":"5711_CR13","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1182\/blood.V122.21.4853.4853","volume":"122","author":"F Mahlert","year":"2013","unstructured":"Mahlert F, Schmidt K, Allgaier H, Liu P, M\u00fcller U, Shen WD (2013) Rational development of lipegfilgrastim, a novel long-acting granulocyte colony-stimulating factor, using glycopegylation technology. Blood 122(21):4853","journal-title":"Blood"},{"key":"5711_CR14","doi-asserted-by":"publisher","first-page":"e13548","DOI":"10.1200\/jco.2013.31.15_suppl.e13548","volume":"31","author":"C Scheckermann","year":"2013","unstructured":"Scheckermann C, Schmidt K, Abdolzade-Bavil A, Allgaier H, Mueller UW, Shen WD, Liu P (2013) Lipegfilgrastim: a long-acting, once-per-cycle, glycopegylated recombinant human filgrastim. J Clin Oncol 31:e13548","journal-title":"J Clin Oncol"},{"issue":"12","key":"5711_CR15","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1185\/03007995.2014.962131","volume":"30","author":"A Buchner","year":"2014","unstructured":"Buchner A, Lammerich A, Abdolzade-Bavil A, M\u00fcller U, Bias P (2014) Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers. Curr Med Res Opin 30(12):2523\u20132533","journal-title":"Curr Med Res Opin"},{"key":"5711_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/1471-2407-13-386","volume":"13","author":"I Bondarenko","year":"2013","unstructured":"Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P (2013) Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy. BMC Cancer 13:386\u2013398","journal-title":"BMC Cancer"},{"issue":"4","key":"5711_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/hon.982","volume":"29","author":"R Pettengell","year":"2011","unstructured":"Pettengell R, Schwenkglenks M, Bacon P, Lawrinson S, Duehrsen U (2011) Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis. Hematol Oncol 29(4):177\u2013184","journal-title":"Hematol Oncol"},{"issue":"4","key":"5711_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/bjh.14088","volume":"174","author":"K Kubo","year":"2016","unstructured":"Kubo K, Miyazaki Y, Murayama T, Shimazaki R, Usui N, Urabe A, Hotta T, Tamura K (2016) A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Br J Haematol 174(4):563\u2013570","journal-title":"Br J Haematol"},{"issue":"3","key":"5711_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00520-016-3468-8","volume":"25","author":"C Cerchione","year":"2017","unstructured":"Cerchione C, De Renzo A, Di Perna M et al (2017) Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. Support Care Cancer 25(3):839\u2013845","journal-title":"Support Care Cancer"},{"issue":"4","key":"5711_CR20","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00520-018-4473-x","volume":"27","author":"JP Salmon","year":"2019","unstructured":"Salmon JP, Smakal M, Karanikiotis C, Wojtukiewicz MZ, Omnes Y, DeCosta L, Wetten S, O\u2019Kelly J (2019) Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin\u2019s lymphoma patients receiving high (>\u200920%) FN-risk chemotherapy: results from a prospective observational study. Support Care Cancer 27(4):1449\u20131457","journal-title":"Support Care Cancer"},{"issue":"5","key":"5711_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/1078155215625459","volume":"22","author":"S Mitchell","year":"2016","unstructured":"Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M (2016) Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract 22(5):702\u2013716","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"5711_CR22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/1042819031000103953","volume":"44","author":"A Grigg","year":"2003","unstructured":"Grigg A, Solal-Celigny P, Hoskin P, Taylor K, M A (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 44(9):1503\u20131508","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"5711_CR23","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019\u20135032","journal-title":"Blood"},{"issue":"5","key":"5711_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"5711_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00520-007-0270-7","volume":"16","author":"LI Wagner","year":"2008","unstructured":"Wagner LI, Beaumont JL, Ding B, Malin J, Peterman A, Calhoun E, Cella D (2008) Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N). Support Care Cancer 16(1):47\u201356","journal-title":"Support Care Cancer"},{"issue":"2","key":"5711_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/ejh.13189","volume":"102","author":"T Wolff","year":"2019","unstructured":"Wolff T, Schulz H, Losem C, Reichert D, Hurtz HJ, Sandner R, Harde J, Grebhardt S, Potthoff K, Mueller U, Fietz T (2019) Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study). Eur J Haematol 102(2):174\u2013181","journal-title":"Eur J Haematol"},{"issue":"6","key":"5711_CR27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1078155217714859","volume":"24","author":"TC Bond","year":"2018","unstructured":"Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B (2018) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract 24(6):412\u2013423","journal-title":"J Oncol Pharm Pract"},{"key":"5711_CR28","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fphar.2017.00614","volume":"8","author":"EIH Akpo","year":"2017","unstructured":"Akpo EIH, Jansen IR, Maes E, Simoens S (2017) Cost-utility analysis of lipegfilgrastim compared to pegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in patients with stage ii-iv breast cancer. Front Pharmacol 8:614","journal-title":"Front Pharmacol"},{"issue":"6","key":"5711_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s12282-018-0872-6","volume":"25","author":"L Gao","year":"2018","unstructured":"Gao L, Li SC (2018) Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation. Breast Cancer 25(6):671\u2013680","journal-title":"Breast Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05711-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:31:07Z","timestamp":1631838667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05711-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5711"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05711-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HL declares to have received personal fees from Teva, Amgen, Chugai, Hexal-Sandoz-Novartis, Mundipharma, Accord Healthcare, and G1 Therapeutics; AK has received a grant from Amgen; AS has received grants from Roche and Gilead and personal fees from Roche, Gilead, Celgene, and Janssen; MZ has received personal fees from Novartis, Hexal, Pfizer, Roche; GI, ME, RD, SM, and UM have no disclosures to declare; PB, AB, and AL are employees of Teva and hold stock options in the company<b>.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Confict of interest"}}]}}